Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium
Duygu Durukan
, Michelle Doyle, Gerald Murray, Kaveesha Bodiyabadu, Lenka Vodstrcil, Eric P.F. Chow, Jorgen S. Jensen, Christopher K. Fairley, Ivette Aguirre, and Catriona S. Bradshaw
Author affiliations: Alfred Health, Carlton, Victoria, Australia (D. Durukan, M. Doyle, L. Vodstrcil, E.P.F. Chow, C.K. Fairley, I. Aguirre, C.S. Bradshaw); Monash University, Clayton, Victoria, Australia (D. Durukan, L. Vodstrcil, E.P.F. Chow, C.K. Fairley, C.S. Bradshaw); Royal Children’s Hospital, Parkville, Victoria, Australia (G. Murray, K. Bodiyabadu); The Royal Women’s Hospital, Parkville (G. Murray, K. Bodiyabadu); Statens Serum Institut, Copenhagen, Denmark (J.S. Jensen)
Main Article
Figure
Figure. Clinical approach and treatment for patients with diagnosed macrolide-resistant Mycoplasma genitalium at Melbourne Sexual Health Centre, Australia. PID, pelvic inflammatory disease; STI, sexually transmitted infection. *Routine testing with the ResistancePlus MG assay (SpeeDx, https://plexpcr.com). †Moxifloxacin 400 mg/day for 14 days. ‡Doxycycline 100 mg 2 times/day for 7 days, then moxifloxacin 400 mg/d for 7 days. §Test of cure was recommended 14–28 days after completing antimicrobial treatment and all patients received a reminder. ResistancePlus MG Assay was used for all tests of cure. ¶When sequential therapy failed, patients were given a pristinamycin-based regimen for 10 days, either 1 g 4 times/day alone or 1 g 3 times/day in combination with doxycycline 100 mg 2 times/day. Doxycycline pretreatment also was given to some patients. #Doxycycline 100 mg and sitafloxacin 100 mg taken together 2 times/day for 7 days.
Main Article
Page created: June 08, 2020
Page updated: July 18, 2020
Page reviewed: July 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.